Human studies also demonstrated that T-cells from AML (co-) expressed higher levels of immune checkpoint molecules (PD-1 and TIM3, PD-1 and LAG3) compared to controls and their expression frequency increased with disease progression [165]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.